Plain-English translation of NCT05630638 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing , a newer HIV medication, in pregnant women to see if it works safely during pregnancy and after delivery. Researchers want to understand how pregnancy affects how the body processes this medication, especially in the third trimester. The study compares this medication to a standard HIV treatment that is already widely used.
Many HIV medications that worked well before are no longer effective because the virus has developed resistance to them. This medication offers a newer option, but doctors need to know if it's safe for pregnant women and their babies before recommending it widely.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will randomly receive either the new medication or the standard HIV treatment, taking one tablet once daily. You will continue this treatment through your delivery and for up to 28 weeks after your baby is born. During this time, you'll have regular visits to check your health, your baby's health, and how well the medication is working.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
South Africa
Sponsor
University of Liverpool
Collaborators
Liverpool School of Tropical Medicine, Desmond Tutu Health Foundation
Enrollment target
~76 participants
Started
October 2023
Primary completion
July 2028
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Helen Reynolds
University of Liverpool
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.